Skip to content
PeptideTech
Cart

Home / Research library / Livagen

Bioregulators · Peptides

Livagen: molecular data, studies & sources

Livagen is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C18H31N5O9
Molecular weight (MW)
461.5 g/mol
PubChem compound ID
87919683
Record title
Livagen

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 87919683 · retrieved 2026-09-21

2D molecular structure for Livagen, PubChem CID 87919683
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(4S)-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
InChIKey
IKVDKWACACMDLR-BJDJZHNGSA-N
SMILES
C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
Machine-readable PubChem source

Identifiers & sequence

PubChem CID
87919683
InChIKey
IKVDKWACACMDLR-BJDJZHNGSA-N

Peptide sequence · 4 residues (one-letter code; X marks a residue without a one-letter code)

KEDA

Condensed notation with terminal groups and non-standard residues

H-Lys-Glu-Asp-Ala-OH

Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.

Calculated molecular descriptors
Monoisotopic (exact) mass461.2122 Da
Heavy atoms32
Hydrogen-bond donors8
Hydrogen-bond acceptors8
Rotatable bonds16
Topological polar surface area251.2 Ų
Calculated logP (Crippen)-2.66
Rings0
Stereocenters4
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Livagen as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Livagen, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

    Preclinical research, reviews & other publications

    Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

    1. Research publication · design requires review

      [Genomic instability in atherosclerosis].

      Dzhokhadze TA, Buadze TZh, Gaiozishvili MN et al. · Georgian medical news · 2014

      PMID 25541832

    2. Research publication · design requires review

      Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.

      Lezhava T, Jokhadze T · Annals of the New York Academy of Sciences · 2007

      PMID 17460203 · DOI: 10.1196/annals.1395.043

    3. Preclinical / laboratory research

      Tissue-specific effects of peptides.

      Khavinson VK · Bulletin of experimental biology and medicine · 2001

      PMID 11713572 · DOI: 10.1023/a:1013058701974

    4. Research publication · design requires review

      Effects of short peptides on lymphocyte chromatin in senile subjects.

      Khavinson VKh, Lezhava TA, Malinin VV et al. · Bulletin of experimental biology and medicine · 2004

      PMID 15085253 · DOI: 10.1023/b:bebm.0000024393.40560.05

    5. Research publication · design requires review

      [Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].

      · Georgian medical news · 2014

      PMID 25341254

    Livagen supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    Livagen for sale: compare prices, sizes and forms from every tracked supplier →

    SupplierRecorded packagesExample source listing
    Amino USAUSD20mg Vial1 recorded offers20mg Vial · $50.00Checked Oct 13, 2026Supplier listing, Livagen 20mg Vial, Amino USA, opens in a new tab

    Reference sources & further reading

    The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

    Search for additional research

    These links run searches; their results have not been individually reviewed and can include unrelated compounds.

    Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

    Related research profiles